ESMO treatment (tx) guideline adherence in patients (pts) with lung cancer (LC) with EGFR or ALK (EGFR/ALK) alterations: a WAYFIND-R registry-based study
WAYFIND-R (NCT04529122) is a multi-country, multi-site, prospective cancer registry that collects real-world data from adult patients diagnosed with a solid tumour and profiled with next-generation sequencing (NGS). This poster describes different care pathways for metastatic lung cancer patients with actionable ALK or EGFR alterations detected by NGS.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.